REVIEW Clomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SRI), as the active main metabolite desmethyclomipramine acts preferably as an inhibitor of noradrenaline reuptake. α1-receptor blockage and β-down-regulation have been noted and most likely play a role in the short term effects of clomipramine. A blockade of sodium-channels and NDMA-receptors might, as with other tricyclics, account for its effect in chronic pain, in particular the neuropathic type.
Albert U, Aguglia E, Maina G, Bogetto F (November 2002). Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 63 (11): 1004-9. PMID 12444814.
Greist, JH (Jan 1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Archives of General Psychiatry. 52 1 (1): 53-60. PMID 7811162.
Millan MJ, Gobert A, Lejeune F, et al. (August 2001). S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. The Journal of Pharmacology and Experimental Therapeutics 298 (2): 565-80. PMID 11454918
Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (March 1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molecular Pharmacology 43 (3): 320-7. PMID 7680751.